mexiletine has been researched along with Aura in 9 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a patient with lidocaine-responsive neonatal epilepsy treated successfully with oral mexiletine." | 7.79 | Oral mexiletine for lidocaine-responsive neonatal epilepsy. ( Hirose, S; Nakazawa, M; Niijima, S; Okumura, A; Shimizu, T; Shimono, K; Yamashita, S, 2013) |
| "Twenty-four patients with refractory epilepsy were treated with mexiletine as an additional antiepileptic drug." | 5.09 | [Clinical applications and the effect of mexiletine on refractory epilepsies]. ( Enoki, H; Hata, H; Kobayashi, K; Maniwa, S; Ohmori, I; Ohta, H, 2000) |
| "We report a patient with lidocaine-responsive neonatal epilepsy treated successfully with oral mexiletine." | 3.79 | Oral mexiletine for lidocaine-responsive neonatal epilepsy. ( Hirose, S; Nakazawa, M; Niijima, S; Okumura, A; Shimizu, T; Shimono, K; Yamashita, S, 2013) |
| "In preparation for a prospective controlled study of mexiletine in the treatment of epilepsy, a preliminary study of serum concentrations after multiple doses was performed with 8 institutionalized Caucasian adult males with uncontrolled seizures and similar weight, medical regimen, and seizure classification." | 3.65 | A multiple-dose study of mexiletine (Kö 1173). ( Brock, JT; Cereghino, JJ; Kupferberg, HJ; Penry, JK; Smith, LD; Van Meter, JC; White, BG, 1975) |
| "Mexiletine was subsequently used in a second infant with reduction in seizure frequency." | 1.46 | Infantile Epileptic Encephalopathy Associated With SCN2A Mutation Responsive to Oral Mexiletine. ( Foster, LA; Henry, TR; Johnson, MR; Karachunski, PI; MacDonald, JT; Moran, BP; Nascene, DR; Raymond, GV, 2017) |
| ", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule." | 1.43 | Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents. ( Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anger, T | 1 |
| Madge, DJ | 1 |
| Mulla, M | 1 |
| Riddall, D | 1 |
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Waszkielewicz, AM | 1 |
| Gunia-Krzyżak, A | 1 |
| Powroźnik, B | 1 |
| Słoczyńska, K | 1 |
| Pękala, E | 1 |
| Walczak, M | 1 |
| Bednarski, M | 1 |
| Żesławska, E | 1 |
| Nitek, W | 1 |
| Marona, H | 1 |
| Foster, LA | 1 |
| Johnson, MR | 1 |
| MacDonald, JT | 1 |
| Karachunski, PI | 1 |
| Henry, TR | 1 |
| Nascene, DR | 1 |
| Moran, BP | 1 |
| Raymond, GV | 1 |
| Nakazawa, M | 1 |
| Okumura, A | 1 |
| Niijima, S | 1 |
| Yamashita, S | 1 |
| Shimono, K | 1 |
| Hirose, S | 1 |
| Shimizu, T | 1 |
| Enoki, H | 1 |
| Hata, H | 1 |
| Ohmori, I | 1 |
| Maniwa, S | 1 |
| Ohta, H | 1 |
| Kobayashi, K | 1 |
| Cereghino, JJ | 2 |
| Wilder, BJ | 1 |
| Kupferberg, HJ | 2 |
| Yonekawa, WD | 1 |
| Perchalski, RJ | 1 |
| Ramsey, RE | 1 |
| White, BG | 2 |
| Penry, JK | 2 |
| Smith, LD | 2 |
| Brock, JT | 1 |
| Van Meter, JC | 1 |
| Kohyama, J | 1 |
| Shimohira, M | 1 |
| Watanabe, S | 1 |
| Fukuda, C | 1 |
| Iwakawa, Y | 1 |
2 reviews available for mexiletine and Aura
| Article | Year |
|---|---|
Medicinal chemistry of neuronal voltage-gated sodium channel blockers.
Topics: Amyotrophic Lateral Sclerosis; Analgesics; Anticonvulsants; Epilepsy; Humans; Ion Channel Gating; Mo | 2001 |
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
1 trial available for mexiletine and Aura
| Article | Year |
|---|---|
[Clinical applications and the effect of mexiletine on refractory epilepsies].
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Child; Child, Preschool; Drug Therapy, Combination; Elect | 2000 |
6 other studies available for mexiletine and Aura
| Article | Year |
|---|---|
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Topics: Amino Alcohols; Animals; Anticonvulsants; Chemistry, Physical; Dose-Response Relationship, Drug; Dru | 2016 |
Infantile Epileptic Encephalopathy Associated With SCN2A Mutation Responsive to Oral Mexiletine.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Anticonvulsants; Epilepsy; Humans; Infant; Infant, New | 2017 |
Oral mexiletine for lidocaine-responsive neonatal epilepsy.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Electroencephalography; Epilepsy; Humans; Infant, Newb | 2013 |
A single-dose study of mexiletine (Kö 1173).
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Humans; Male; Mexiletine; Middle | 1975 |
A multiple-dose study of mexiletine (Kö 1173).
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Humans; Male; Mexiletine; Propyl | 1975 |
Mexiletine hydrochloride in an infant with intractable epilepsy.
Topics: Electroencephalography; Epilepsy; Female; Humans; Infant; Mexiletine | 1988 |